442 related articles for article (PubMed ID: 31223045)
21. Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors.
Beavis PA; Divisekera U; Paget C; Chow MT; John LB; Devaud C; Dwyer K; Stagg J; Smyth MJ; Darcy PK
Proc Natl Acad Sci U S A; 2013 Sep; 110(36):14711-6. PubMed ID: 23964122
[TBL] [Abstract][Full Text] [Related]
22. Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune Responses.
Young A; Ngiow SF; Barkauskas DS; Sult E; Hay C; Blake SJ; Huang Q; Liu J; Takeda K; Teng MWL; Sachsenmeier K; Smyth MJ
Cancer Cell; 2016 Sep; 30(3):391-403. PubMed ID: 27622332
[TBL] [Abstract][Full Text] [Related]
23. Measurement of CD73 enzymatic activity using luminescence-based and colorimetric assays.
Allard B; Cousineau I; Spring K; Stagg J
Methods Enzymol; 2019; 629():269-289. PubMed ID: 31727245
[TBL] [Abstract][Full Text] [Related]
24. CD73 contributes to anti-inflammatory properties of afferent lymphatic endothelial cells in humans and mice.
Eichin D; Pessia A; Takeda A; Laakkonen J; Bellmann L; Kankainen M; Imhof BA; Stoitzner P; Tang J; Salmi M; Jalkanen S
Eur J Immunol; 2021 Jan; 51(1):231-246. PubMed ID: 32970335
[TBL] [Abstract][Full Text] [Related]
25. CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer.
Loi S; Pommey S; Haibe-Kains B; Beavis PA; Darcy PK; Smyth MJ; Stagg J
Proc Natl Acad Sci U S A; 2013 Jul; 110(27):11091-6. PubMed ID: 23776241
[TBL] [Abstract][Full Text] [Related]
26. Prognostic significance and immune correlates of CD73 expression in renal cell carcinoma.
Tripathi A; Lin E; Xie W; Flaifel A; Steinharter JA; Stern Gatof EN; Bouchard G; Fleischer JH; Martinez-Chanza N; Gray C; Mantia C; Thompson L; Wei XX; Giannakis M; McGregor BA; Choueiri TK; Agarwal N; McDermott DF; Signoretti S; Harshman LC
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33177176
[TBL] [Abstract][Full Text] [Related]
27. Structural investigation on thiazolo[5,4-d]pyrimidines to obtain dual-acting blockers of CD73 and adenosine A
Varano F; Catarzi D; Vincenzi F; Pasquini S; Pelletier J; Lopes Rangel Fietto J; Espindola Gelsleichter N; Sarlandie M; Guilbaud A; Sévigny J; Varani K; Colotta V
Bioorg Med Chem Lett; 2020 May; 30(9):127067. PubMed ID: 32165041
[TBL] [Abstract][Full Text] [Related]
28. CD73 immune checkpoint defines regulatory NK cells within the tumor microenvironment.
Neo SY; Yang Y; Record J; Ma R; Chen X; Chen Z; Tobin NP; Blake E; Seitz C; Thomas R; Wagner AK; Andersson J; de Boniface J; Bergh J; Murray S; Alici E; Childs R; Johansson M; Westerberg LS; Haglund F; Hartman J; Lundqvist A
J Clin Invest; 2020 Mar; 130(3):1185-1198. PubMed ID: 31770109
[TBL] [Abstract][Full Text] [Related]
29. Orally Bioavailable Small-Molecule CD73 Inhibitor (OP-5244) Reverses Immunosuppression through Blockade of Adenosine Production.
Du X; Moore J; Blank BR; Eksterowicz J; Sutimantanapi D; Yuen N; Metzger T; Chan B; Huang T; Chen X; Chen Y; Duong F; Kong W; Chang JH; Sun J; Zavorotinskaya T; Ye Q; Junttila MR; Ndubaku C; Friedman LS; Fantin VR; Sun D
J Med Chem; 2020 Sep; 63(18):10433-10459. PubMed ID: 32865411
[TBL] [Abstract][Full Text] [Related]
30. Anti-CD73 therapy impairs tumor angiogenesis.
Allard B; Turcotte M; Spring K; Pommey S; Royal I; Stagg J
Int J Cancer; 2014 Mar; 134(6):1466-73. PubMed ID: 23982901
[TBL] [Abstract][Full Text] [Related]
31. CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression.
Jin D; Fan J; Wang L; Thompson LF; Liu A; Daniel BJ; Shin T; Curiel TJ; Zhang B
Cancer Res; 2010 Mar; 70(6):2245-55. PubMed ID: 20179192
[TBL] [Abstract][Full Text] [Related]
32. Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer.
Allard B; Turcotte M; Stagg J
Expert Opin Ther Targets; 2014 Aug; 18(8):863-81. PubMed ID: 24798880
[TBL] [Abstract][Full Text] [Related]
33. High-Throughput Screening Assays for Cancer Immunotherapy Targets: Ectonucleotidases CD39 and CD73.
Kumar M; Lowery R; Kumar V
SLAS Discov; 2020 Mar; 25(3):320-326. PubMed ID: 31868071
[TBL] [Abstract][Full Text] [Related]
34. Biomimetic nanodrug blocks CD73 to inhibit adenosine and boosts antitumor immune response synergically with photothermal stimulation.
Li T; Zhang X; Shi C; Liu Q; Zhao Y
J Nanobiotechnology; 2024 Apr; 22(1):214. PubMed ID: 38689291
[TBL] [Abstract][Full Text] [Related]
35. The metabolic milieu in melanoma: Role of immune suppression by CD73/adenosine.
Passarelli A; Tucci M; Mannavola F; Felici C; Silvestris F
Tumour Biol; 2019 Apr; 42(4):1010428319837138. PubMed ID: 30957676
[TBL] [Abstract][Full Text] [Related]
36. The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets.
Allard B; Longhi MS; Robson SC; Stagg J
Immunol Rev; 2017 Mar; 276(1):121-144. PubMed ID: 28258700
[TBL] [Abstract][Full Text] [Related]
37. Ecto-5'-nucleotidase (CD73) promotes tumor angiogenesis.
Wang L; Tang S; Wang Y; Xu S; Yu J; Zhi X; Ou Z; Yang J; Zhou P; Shao Z
Clin Exp Metastasis; 2013 Jun; 30(5):671-80. PubMed ID: 23508889
[TBL] [Abstract][Full Text] [Related]
38. [A new generation of immunotherapies targeting the CD39/CD73/adenosine pathway to promote the anti-tumor immune response].
Gros L; Paturel C; Perrot I; Bensussan A; Eliaou JF; Bastid J; Bonnefoy N
Med Sci (Paris); 2020 Feb; 36(2):112-115. PubMed ID: 32129745
[No Abstract] [Full Text] [Related]
39. Requirement of NK cells for selective A2A receptor blockade to suppress CD73+ tumor metastasis.
Qin L; Thompson LF; Kuzel TM; Zhang B
Immunotherapy; 2014; 6(1):19-21. PubMed ID: 24341879
[TBL] [Abstract][Full Text] [Related]
40. Generating tumor-selective conditionally active biologic anti-CTLA4 antibodies via protein-associated chemical switches.
Chang HW; Frey G; Liu H; Xing C; Steinman L; Boyle WJ; Short JM
Proc Natl Acad Sci U S A; 2021 Mar; 118(9):. PubMed ID: 33627407
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
